Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
08:44am, Wednesday, 30'th Nov 2022
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal
02:18pm, Tuesday, 29'th Nov 2022
Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.
Why Is Axsome Therapeutics (AXSM) Stock Up 32% Today?
12:35pm, Monday, 28'th Nov 2022
Axsome Therapeutics (NASDAQ: AXSM ) stock is soaring higher on Monday after releasing positive results from a Phase 3 clinical trial. That Phase 3 clinical trial covers Alzheimer's Disease drug candid
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
09:07am, Monday, 28'th Nov 2022
Biogen stock toppled Monday after a report suggested its experimental Alzheimer's treatment caused a patient's fatal brain hemorrhage. The post Biogen Dives On Reports Of Alzheimer's Death While Axsom
Axsome's stock rallies 15% on promising findings for its experimental Alzheimer's drug
08:36am, Monday, 28'th Nov 2022
Shares of Axsome Therapeutics Inc. AXSM, +1.07% jumped 15.5% in premarket trading on Monday after the company said its Alzheimer's treatment candidate met the primary and secondary endpoints in a Phas
Want to Double Your Money? Buying These Stocks Could be a Genius Move
06:00am, Monday, 28'th Nov 2022
These stocks are undervalued considering their long-term growth potential.
3 Growth Stocks to Buy That Could Skyrocket
05:55am, Monday, 28'th Nov 2022
The future looks promising for all three of these stocks.
Prediction: This Growth Stock Could Double in 2023
09:45am, Thursday, 24'th Nov 2022
The next year should be a busy one for this drugmaker.
Axsome: Strong Earnings Signal More Upside
02:40am, Thursday, 24'th Nov 2022
As Auvelity is recently approved, Axsome now has two solid drugs that are likely to generate significant market traction. Toward year-end, Axsome will report data of the ACCORD trial that further woul
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
07:00am, Wednesday, 23'rd Nov 2022
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
06:30am, Sunday, 20'th Nov 2022
Innovative products and services could keep these companies growing.
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.
05:52am, Friday, 18'th Nov 2022
The good times could keep on rolling for these big winners.
Is Axsome Therapeutics Stock a Buy Now?
10:07am, Friday, 11'th Nov 2022
The company seems to be coming into its own.
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
04:20pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.
Why Axsome Therapeutics Stock Is Bolting Higher Today
01:41pm, Tuesday, 08'th Nov 2022
The biotech's promising Q3 earnings report has investors excited about the future.
